荧光膀胱镜辅助整块经尿道电切对比传统电切治疗非肌层浸润性膀胱癌:FLEBER 研究方案
FLEBER 研究为单中心、前瞻性、开放标签随机对照试验,计划纳入 160 例肿瘤长径 6–30 mm 的非肌层浸润性膀胱癌患者,1:1 随机接受光动力诊断辅助整块经尿道电切(PDD-EBTUR)或传统电切(PDD-cTURBT),均术后即刻单次表柔比星膀胱灌注。主要终点为病理证实的低或中危患者术后 2 年无复发生存。
要点
- PDD-EBTUR 旨在整块切除肿瘤及周围正常组织,可能减少肿瘤播散与种植复发。
- 研究聚焦肿瘤长径 6–30 mm 的低或中危非肌层浸润性膀胱癌患者。
- 所有患者均接受术后即刻单次表柔比星膀胱灌注,随访 2 年每 3 个月膀胱镜和尿细胞学检查。
核心结论
- 本试验旨在评估 PDD-EBTUR 相比 PDD-cTURBT 在低或中危非肌层浸润性膀胱癌患者中的优越性。
研究设计与样本
- 单中心、前瞻性、开放标签随机对照试验,计划纳入 160 例需行 TURBT 的非肌层浸润性膀胱癌患者。
- 入组肿瘤长径须在 6 至 30 mm 之间,按 1:1 随机分配至 PDD-EBTUR 组(80 例)和 PDD-cTURBT 组(80 例)。
关键数值与推荐
- 主要终点为病理证实的低或中危非肌层浸润性膀胱癌术后 2 年无复发生存。
- 所有患者均接受术后即刻单次表柔比星膀胱灌注。
- 随访 2 年期间每 3 个月进行膀胱镜和尿细胞学检查。
临床怎么用
- 若证实 PDD-EBTUR 优越,可能改变低或中危非肌层浸润性膀胱癌的 TURBT 标准术式。
局限性
- 研究方案未报告样本量计算依据、盲法设置及统计分析方法等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transurethral resection of bladder tumor (TURBT) is an essential procedure both for the treatment and staging of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). The dissemination of cancer cells during resection and the consequent seeding into the bladder mucosa is the main cause of post-TURBT intravesical recurrence. Although the tumor dissemination is inevitable during conventional TURBT (cTURBT), this drawback can be overcome by tumor resection in one piece with intact surrounding normal tissues, referred to as en bloc resection. We previously described the photodynamic diagnosis (PDD)-assisted en bloc TURBT (EBTUR) technique and its favorable outcomes. Based on our preliminary studies, this randomized controlled trial was designed to evaluate the superiority of PDD-EBTUR to PDD-cTURBT. METHODS: The FLEBER study is a single-center randomized controlled trial in NMIBC patients who require TURBT. The longest diameter of the tumor must be between 6 and 30 mm. A total of 160 eligible patients will be enrolled after screening and randomly allocated to the PDD-EBTUR (experimental) and PDD-cTURBT (control) groups in a 1:1 ratio (80 cases to 80 cases). All patients will be treated using a single, immediate postoperative intravesical chemotherapy with epirubicin. The primary endpoint of this trial is the 2-year recurrence-free survival after surgery in pathologically proven low- or intermediate-risk NMIBC. All patients will be monitored by cystoscopy and urine cytology every 3 months for 2 years. Patient data including adverse events and complications, and data from frequency volume charts, pain scales, and health-related QOL questionnaires will be collected before and after the TURBT at indicated visits. DISCUSSION: The goal of this trial is to determine the potential benefits of PDD-cTURBT and PDD-EBTUR followed by a single immediate postoperative intravesical chemotherapy in patients with low- or intermediate-risk NMIBC who undergo TURBT. Ultimately, our findings will lead to the development of better interventions and potentially change the standard of care. TRIAL REGISTRATION: This clinical trial was prospectively registered with the UMIN Clinical Trials Registry on 1 August 2020. The reference number is UMIN000041273 , and the Ethics Committee of Nara Medical University Approval ID is 2702.
引用
- Miyake M, Nishimura N, Inoue T, et al. Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study). Trials. 2021. PMID: 33579327. doi:10.1186/s13063-021-05094-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。